November 5, 2026
News Summary
-
Q3 2026 net sales of**$836 million**
-
Q3 2026 GAAP gross margin of52.9%, GAAP diluted loss per share of**($0.01)**
-
Q3 2026 adjusted gross margin of54.5%,adjusted EBITDA marginof17.3%, adjusted EPS of**$0.29**
-
**Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™portfolio with the launch of the Surity™**Urinary Management System
-
Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30
CHARLOTTE, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.
"We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth."
Q3 2026 Summary Results (Reported)
Gross profit and adjusted EBITDA include a $39 million benefit from the refinement of our estimate to eliminate unrealized profit in inventory. The adjustment reduces the reported net loss and increases adjusted net income by approximately $30 million. This amount represents the cumulative impact of the revised estimate and equivalent impacts are not expected in future.
| (in millions, except per share amount and percentages) | | Q3 26 | | Q3 25 | | YoY |
| | | | | | | |
| Net Sales | | $836 | | $904 | | (7.6%) |
| Gross Profit | | $443 | | $441 | | 0.3% |
| Gross Margin | | 52.9% | | 48.8% | | |
| Net Loss Attributable to Dentsply Sirona | | ($2) | | ($427) | | NM |
| Diluted Loss Per Share1 | | ($0.01) | | ($2.14) | | NM |
Q3 2026 Summary Results (Non-GAAP)
| (in millions, except per share amount and percentages) | | Q3 26 | | Q3 25 | | YoY |
| | | | | | | |
| Constant Currency Sales | | | | | | (7.0%) |
| Adjusted EBITDA | | $146 | | $167 | | (13.3%) |
| Adjusted EBITDA Margin | | 17.3% | | 18.4% | | |
| Adjusted EPS | | $0.29 | | $0.42 | | (29.4%) |
NM - not meaningful Percentages are based on actual values and may not reconcile due to rounding. [1] Weighted-average shares outstanding used to calculate diluted loss per share for the third quarter of 2026 excludes potential dilutive common shares.
Q3 2026 Results by Region and Segment (Reported and Non-GAAP) (in millions, except percentages)
| | | | | | Percentage Change |
| Net Sales by Segment | | | Three Months Ended September 30, 2026 vs. 2025 |
| | | | | | | | | Americas | | EMEA | | APAC |
| | | | | | | | | | | | | | | | |
| | 2026 | | 2025 | | As Reported1 | Constant Currency1 | | As Reported | Constant Currency | | As Reported | Constant Currency | | As Reported | Constant Currency |
| | | | | | | | | | | | | | | | |
| Connected Technology Solutions | $ | 230 | | $ | 259 | | (11.0)% | (10.1)% | | (21.6)% | (21.9)% | | (5.5)% | (4.2)% | | (4.7)% | (2.5)% |
| Essential Dental Solutions | | 343 | | | 357 | | (4.0)% | (3.6)% | | (0.6)% | (0.8)% | | (7.7)% | (6.5)% | | (4.4)% | (4.2)% |
| Orthodontic and Implant Solutions | | 171 | | | 205 | | (16.6)% | (16.2)% | | (22.9)% | (23.1)% | | (13.5)% | (12.3)% | | (7.3)% | (7.2)% |
| Wellspect Healthcare | | 92 | | | 83 | | 10.1% | 11.0% | | 77.3% | 78.6% | | 1.2% | 2.0% | | (1.0)% | 4.1% |
| Total | $ | 836 | | $ | 904 | | (7.6)% | (7.0)% | | (9.4)% | (9.6)% | | (6.7)% | (5.6)% | | (5.2)% | (4.3)% |
| (1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales. |
Cash Flow and Liquidity
Operating cash flow in the third quarter of 2026 was $32 million, compared to $79 million in the third quarter of 2025, primarily driven by unfavorable working capital. Free cash flow, a Non-GAAP measure, in the third quarter of 2026 was $0 million compared to $40 million in the third quarter of 2025. In the third quarter of 2026, the Company repurchased 1.2 million shares of its common stock for a total of approximately $13 million, resulting in a total of $25 million returned to stockholders through share repurchases in the first nine months of 2026. The Company had $195 million of cash and cash equivalents as of September 30, 2026.
2026 Outlook
The Company is updating its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds.
Without unreasonable effort, we are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.
Conference Call/Webcast Information Dentsply Sirona's management team will host an investor conference call and live webcast on November 5, 2026 at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at http://register-conf.media-server.com/register/BI087bbe14635a47a484497a4e4376efc9. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.
About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
_(1).png)
